A systematic review as a method of gathering scientific evidence into clinical guidelines: CHEST-2019 guideline for the therapy pulmonary arterial hypertension in adults


Cite item

Full Text

Abstract

The updated fourth version of the CHEST guideline presents the evidence base and treatment algorithm for pulmonary arterial hypertension in adults. The CHEST approach to creating clinical guidelines differs from the European one (ESC/ERS) and, in fact, consists in a systematic review of clinical trials and a sammary of their postulates.

About the authors

A A Shmalts

Bakoulev Scientific Center for Cardiovascular Surgery; Russian State Medical Postgraduate Academy

Moscow, Russia

S V Gorbachevsky

Bakoulev Scientific Center for Cardiovascular Surgery; Russian State Medical Postgraduate Academy

Moscow, Russia

References

  1. Galie N, Humbert M, Vachiery J.L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. doi: 10.1093/eurheartj/ehv317
  2. Galie N, Humbert M, Vachiery J.L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC),International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903-75. doi: 10.1183/13993003.01032-2015
  3. Galiè N, Channick R.N, Frantz R.P, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1). pii: 1801889. doi: 10.1183/13993003.01889-2018
  4. Легочная гипертензия. Российские клинические рекомендации, 2016. Доступно по ссылке: http://cr.rosminzdrav.ru /schema.html?id=136#/text
  5. Klinger J.R, Elliott C.G, Levine D.J, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest. 2019;155(3):565-86. doi: 10.1016/j.chest.2018.11.030
  6. Mc Crory D.C, Coeytaux R.R, Schmit K.M, et al. AHRQ Comparative Effectiveness Reviews. Pulmonary Arterial Hypertension: Screening, Management, and Treatment. Rockville (MD): Agency for Healthcare Research and Quality (US), 2013.
  7. Taichman D.B, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014;146(2):449-75. doi: 10.1378/chest.14-0793
  8. Мартынюк Т.В., Чазова И.Е. Стратегия медикаментозного лечения легочной артериальной гипертензии в свете современных зарубежных рекомендаций. Системные гипертензии. 2016;13(2):46-64. doi: 10.26442/2075-082x_13.2.46-64
  9. Andrews J, Guyatt G, Oxman A.D, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719-25. doi: 10.1016/j.jclinepi.2012.03.013
  10. Balshem H, Helfand M, Schünemann H.J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-6. doi: 10.1016/j.jclinepi.2010.07.015
  11. Simonneau G, Torbicki A, Hoeper M.M, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40(4):874-80. doi: 10.1183/ 09031936.00137511
  12. Sitbon O, Channick R, Chin K.M, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522-33. doi: 10.1056/nejmoa1503184
  13. Jing Z.C, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127(5):624-33. doi: 10.1161/circulationaha.112.124388
  14. Mc Laughlin V, Channick R.N, Ghofrani H.A, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46(2):405-13. doi: 10.1183/13993003.02044-2014
  15. Galie N, Barbera J.A, Frost A.E, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834-44. doi: 10.1056/nejmoa1413687
  16. Zhuang Y, Jiang B, Gao H, Zhao W. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertens Res. 2014;37(6):507-12. doi: 10.1038/hr.2014.28
  17. Tapson V.F, Jing Z.C, Xu K.F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013;144(3):952-8. doi: 10.1378/chest.12-2875
  18. Hoeper M.M, Simonneau G, Corris P.A, et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J. 2017;50(3):1602425. doi: 10.1183/13993003.02425-2016
  19. Chia K.S, Wong P.K, Faux S.G, et al. The benefit of exercise training in pulmonary hypertension: a clinical review. Intern Med J. 2017;47(4):361-9. doi: 10.1111/imj.13159
  20. Inagaki T, Terada J, Tanabe N, et al. Home - based pulmonary rehabilitation in patients with inoperable or residual chronic thromboembolic pulmonary hypertension: a preliminary study. Respir Investig. 2014;52(6):357-64. doi: 10.1016/j.resinv.2014.07.002
  21. Zafrir B. Exercise training and rehabilitation in pulmonary arterial hypertension: rationale and current data evaluation. J Cardiopulm Rehabil Prev. 2013;33(5):263-73. doi: 10.1097/hcr.0b013e3182a0299a
  22. Ganderton L, Jenkins S, Gain K, et al. Short term effects of exercise training on exercise capacity and quality of life in patients with pulmonary arterial hypertension: protocol for a randomized controlled trial. BMC Pulm Med. 2011;11:25. doi: 10.1186/1471-2466-11-25
  23. Weinstein A.A, Chin L.M, Keyser R.E, et al. Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension. Respir Med. 2013;107(5):778-84. doi: 10.1016/j.rmed.2013.02.006
  24. Ehlken N, Lichtblau M, Klose H, et al. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension: a prospective, randomized, controlled trial. Eur Heart J. 2016;37(1):35-44. doi: 10.1093/eurheartj/ehv337
  25. Morris N.R, Kermeen F.D, Holland A.E. Exercise - based rehabilitation programmes for pulmonary hypertension. Cochrane Database Syst Rev. 2017;1:CD011285. doi: 10.1002/14651858.cd011285.pub2
  26. Saglam M, Arikan H, Vardar-Yagli N, et al. Inspiratory muscle training in pulmonary arterial hypertension. J Cardiopulm Rehabil Prev. 2015;35(3):198-206. doi: 10.1097/hcr.0000000000000117
  27. Ezedunukwe I.R, Enuh H, Nfonoyim J, Enuh Collins U. Anticoagulation therapy versus placebo for pulmonary hypertension. Cochrane Database Syst Rev. 2014;(6):CD010695. doi: 10.1002/ 14651858.cd010695.pub2
  28. Olsson K.M, Delcroix M, Ghofrani H.A, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014;129(1):57-65. doi: 10.1161/CIRCULATIONAHA.113.004526
  29. Preston I.R, Roberts K.E, Miller D.P, et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation. 2015;132(25):2403-11. doi: 10.1161/circulationaha.115.018435
  30. Kang B.J, Oh Y-M, Lee S-D, Lee J.S. Survival benefits of warfarin in Korean patients with idiopathic pulmonary arterial hypertension. Korean J Intern Med. 2015;30(6):837-45. doi: 10.3904/kjim.2015. 30.6.837
  31. Kawut S.M, Bagiella E, Lederer D.J, et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASASTAT. Circulation. 2011;123(25):2985-93. doi: 10.1161/circulationaha.110.015693
  32. Kawut S.M, Horn E.M, Berekashvili K.K, et al. Selective serotonin reup - take inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther. 2006;19(5):370-4. doi: 10.1016/ j.pupt.2006.01.001
  33. Sitbon O, Gomberg-Maitland M, Granton J, et al. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J. 2019;53(1). pii: 1801908. doi: 10.1183/13993003.01908-2018
  34. Mc Laughlin V.V, Badesch D.B, Delcroix M, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S97-S107. doi: 10.1016/j.jacc.2009.04.007
  35. Шмальц А.А., Горбачевский С.В. Биохимический путь оксида азота в терапиилегочной артериальной гипертензии и результаты исследования RESPITE. Системные гипертензии. 2018;15(2):72-6. doi: 10.26442/ 2075-082x_2018.2.72-76
  36. Шмальц А.А., Горбачевский С.В. Риоцигуат и силденафил в лечении легочной гипертензии: сходства и различия. Пульмонология. 2016;26(1):85-91.
  37. REPLACE. Riociguat replacing PDE-5i therapy evaluated against continued PDE-5i therapy. Сlinical Trials.gov Identifier: NCT02891850.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies